Altimmune, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before October 6, 2025 to Discuss Your Rights – ALT

Core Viewpoint - Altimmune, Inc. faced significant stock price decline following the announcement of disappointing results from its IMPACT Phase 2b MASH trial of Pemvidutide, leading to a class action notice for shareholders [3][4]. Group 1: Company Performance - On June 26, 2025, Altimmune announced topline results from the IMPACT Phase 2b MASH trial, which failed to achieve statistical significance in the primary endpoint of fibrosis reduction [3]. - The stock price of Altimmune dropped from $7.71 per share on June 25, 2025, to $3.61 per share on June 26, 2025, marking a decline of 53.2% in one day [3]. Group 2: Shareholder Actions - Shareholders who purchased shares during the class period from August 10, 2023, to June 25, 2025, are encouraged to contact the Gross Law Firm regarding potential lead plaintiff appointment [3][4]. - The deadline for shareholders to seek lead plaintiff status is October 6, 2025, and there is no cost or obligation to participate in the case [4]. Group 3: Legal Context - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to recover losses incurred by investors due to misleading statements or omissions by companies that artificially inflated stock prices [5].